Immunological Dynamics in MASH: from Landscape Analysis to Therapeutic Intervention

Overview

Journal J Gastroenterol

Specialty Gastroenterology

Date 2024 Oct 14

PMID 39400718

Authors

Lawan Rabiu

Pengchao Zhang

Lukman O Afolabi

Muhammad A Saliu

Salisu M Dabai

Rabiatu B Suleiman

Khalid I Gidado

Mark A Ige

Abdulrahman Ibrahim

Guizhong Zhang

Xiaochun Wan

Affiliations

Soon will be listed here.

Abstract

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), is a multifaceted liver disease characterized by inflammation and fibrosis that develops from simple steatosis. Immune and inflammatory pathways have a central role in the pathogenesis of MASH, yet, how to target immune pathways to treat MASH remains perplexed. This review emphasizes the intricate role that immune cells play in the etiology and pathophysiology of MASH and highlights their significance as targets for therapeutic approaches. It discusses both current strategies and novel therapies aimed at modulating the immune response in MASH. It also highlights challenges in liver-specific drug delivery, potential off-target effects, and difficulties in targeting diverse immune cell populations within the liver. This review is a comprehensive resource that integrates current knowledge with future perspectives in the evolving field of MASH, with the goal of driving forward progress in medical therapies designed to treat this complex liver disease.

Citing Articles

Revisiting the relationship between thyroid function and metabolic dysfunction-associated steatotic liver disease in the era of resmetirom.

Sakane S, Hikita H J Gastroenterol. 2025; 60(3):389-391.

PMID: 39847088 DOI: 10.1007/s00535-025-02214-2.

References

Rinella M, Lazarus J, Ratziu V, Francque S, Sanyal A, Kanwal F . A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023; 78(6):1966-1986. PMC: 10653297. DOI: 10.1097/HEP.0000000000000520. View

Tilg H, Moschen A . Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010; 52(5):1836-46. DOI: 10.1002/hep.24001. View

Tsuchida T, Friedman S . Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017; 14(7):397-411. DOI: 10.1038/nrgastro.2017.38. View

Moayedfard Z, Sani F, Alizadeh A, Bagheri Lankarani K, Zarei M, Azarpira N . The role of the immune system in the pathogenesis of NAFLD and potential therapeutic impacts of mesenchymal stem cell-derived extracellular vesicles. Stem Cell Res Ther. 2022; 13(1):242. PMC: 9175371. DOI: 10.1186/s13287-022-02929-6. View

Tilg H, Byrne C, Targher G . NASH drug treatment development: challenges and lessons. Lancet Gastroenterol Hepatol. 2023; 8(10):943-954. DOI: 10.1016/S2468-1253(23)00159-0. View

Alukal J, Thuluvath P . Reversal of NASH fibrosis with pharmacotherapy. Hepatol Int. 2019; 13(5):534-545. DOI: 10.1007/s12072-019-09970-3. View

Friedman S, Neuschwander-Tetri B, Rinella M, Sanyal A . Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018; 24(7):908-922. PMC: 6553468. DOI: 10.1038/s41591-018-0104-9. View

Koo S, Park E, Lee C . Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma. Exp Mol Med. 2020; 52(8):1209-1219. PMC: 8080649. DOI: 10.1038/s12276-020-0480-3. View

Huby T, Gautier E . Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol. 2021; 22(7):429-443. PMC: 8570243. DOI: 10.1038/s41577-021-00639-3. View

10.

Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo J, Eberl G . Innate Lymphoid Cells: 10 Years On. Cell. 2018; 174(5):1054-1066. DOI: 10.1016/j.cell.2018.07.017. View

11.

Nijhuis J, Rensen S, Slaats Y, van Dielen F, Buurman W, Greve J . Neutrophil activation in morbid obesity, chronic activation of acute inflammation. Obesity (Silver Spring). 2009; 17(11):2014-8. DOI: 10.1038/oby.2009.113. View

12.

Ma D, Ha J, Yoon K, Kang I, Choi T, Kim S . Innate Immune System in the Pathogenesis of Non-Alcoholic Fatty Liver Disease. Nutrients. 2023; 15(9). PMC: 10181169. DOI: 10.3390/nu15092068. View

13.

Sutti S, Albano E . Adaptive immunity: an emerging player in the progression of NAFLD. Nat Rev Gastroenterol Hepatol. 2019; 17(2):81-92. PMC: 7222953. DOI: 10.1038/s41575-019-0210-2. View

14.

Sawada K, Chung H, Softic S, Moreno-Fernandez M, Divanovic S . The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease. Cell Metab. 2023; 35(11):1852-1871. PMC: 10680147. DOI: 10.1016/j.cmet.2023.10.009. View

15.

Soto A, Spongberg C, Martinino A, Giovinazzo F . Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond. Biomedicines. 2024; 12(2). PMC: 10886580. DOI: 10.3390/biomedicines12020397. View

16.

BasuRay S, Smagris E, Cohen J, Hobbs H . The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation. Hepatology. 2017; 66(4):1111-1124. PMC: 5605398. DOI: 10.1002/hep.29273. View

17.

Bruschi F, Claudel T, Tardelli M, Caligiuri A, Stulnig T, Marra F . The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells. Hepatology. 2017; 65(6):1875-1890. DOI: 10.1002/hep.29041. View

18.

Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio L . Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008; 40(12):1461-5. PMC: 2597056. DOI: 10.1038/ng.257. View

19.

Valenti L, Al-Serri A, Daly A, Galmozzi E, Rametta R, Dongiovanni P . Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010; 51(4):1209-17. DOI: 10.1002/hep.23622. View

20.

Anstee Q, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D . Corrigendum to: "Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort" [J Hepatol (2020) 505-515]. J Hepatol. 2023; 78(5):1085-1086. DOI: 10.1016/j.jhep.2023.02.028. View